Guay DR. An update on the role of nitrofurans in the management of urinary tract infections. [Review]. Drugs 2001;61:353-364.
Hooper DC. New uses for new and old fluoro-
quinolones and the challenge of resistance. Infect Dis 2000;30:243-254.
Hooper DC. Urinary tract agents: Nitrofurantoin and methenamine. In Mandell GL, Dolin R, and Bennet JE (Eds.). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 5th ed. New York: Churchill Livingstone, 2000.
Lipsky BA and Baker CA. Fluoroquinolone toxicity profiles: A review focusing on newer agents. Clin Infect Dis 1999;28:352-364.
Martin JN et al. Emergence of trimethoprim-sul-famethoxazole resistance in the AIDS era. J Infect Dis 1999;180:1809-1818.
Smith JM, Curi AL, and Pavesio CE. Crystalluria with sulphadiazine. Br J Ophthalmol 2001;85:1265-1269.
Walker RC. The fluoroquinolones. Mayo Clin Proc 1999;74:1030-1037.
Wright SW, Wrenn KD, and Haynes ML.
Trimethoprim-sulfamethoxazole resistance among urinary coliform isolates. J Gen Intern Med 1999;14: 606-609.
Was this article helpful?
If you suffer with asthma, you will no doubt be familiar with the uncomfortable sensations as your bronchial tubes begin to narrow and your muscles around them start to tighten. A sticky mucus known as phlegm begins to produce and increase within your bronchial tubes and you begin to wheeze, cough and struggle to breathe.